LeonaBio (LONA) Earnings Date & Reports

Key Takeaways

• LeonaBio (LONA) is a pre-revenue, clinical-stage biopharmaceutical company, so its third-quarter 2026 report will center on net loss per share, research and development (R&D) spending, and cash runway rather than sales.
• Wall Street consensus points to a third-quarter net loss of roughly $0.62 to $0.69 per share, with reported revenue expected at $0.
• In the prior quarter (Q2 2026), LeonaBio posted a net loss of about $19 million, or $0.80 per share, as it continued funding its lead drug programs.
• Investors will focus on progress for lasofoxifene in the Phase 3 ELAINE-3 breast cancer trial and ATH-1105 in ALS (amyotrophic lateral sclerosis, a progressive neurological disease).
• Management has indicated its cash position should support operations into 2028, making any updated spending or financing commentary a key watch item.
• For additional detail, you can review LeonaBio's Major News, Today's Price Move, Price Targets, and Forecast.
• Explore Trending AI Robots to see AI-driven trading strategies currently drawing attention across the market.

Earnings Context and Why It Matters

LeonaBio, formerly Athira Pharma, rebranded in January 2026 after securing global rights to lasofoxifene from Sermonix Pharmaceuticals and completing a roughly $90 million private placement. As a clinical-stage company with no approved products, it generates no revenue, so quarterly results function as a report card on spending discipline and trial execution. The third-quarter 2026 update arrives at a pivotal moment: lasofoxifene's Phase 3 ELAINE-3 trial is more than 50% enrolled with data expected in mid-2027, while ATH-1105 is preparing to advance in ALS. Investors will read the numbers for clues on cash burn, milestone payments, and whether the stated runway into 2028 remains intact.

Earnings Expectations

Because LeonaBio has no commercial revenue, analysts model the quarter primarily on the bottom line. Consensus expectations call for a third-quarter net loss in the range of roughly $0.62 to $0.69 per share, with revenue forecast at $0. For context, the company reported a net loss of about $19 million ($0.80 per share) in Q2 2026 and a larger loss of roughly $32.9 million ($1.73 per share) in Q1 2026 — the latter inflated by a non-cash charge tied to a change in the fair value of a pre-funded warrant. The first-quarter report also highlighted a jump in R&D expense as spending on the newly in-licensed lasofoxifene program ramped up. Heading into this report, investors are watching whether that spending trajectory continues and how it affects the stated cash runway into 2028.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener can help surface trade ideas, trending stocks, breakout candidates, and broader market opportunities far more efficiently than manual screening. For investors following names like LeonaBio, it offers a practical way to identify comparable opportunities and monitor shifting market conditions.

Market Reaction and Investor Sentiment

LeonaBio's shares have historically been volatile around earnings, reflecting its status as a clinical-stage biotech whose valuation is driven more by pipeline milestones than by quarterly profit-and-loss results. Past earnings reactions have ranged from modest gains to single-digit declines, and the stock has experienced a notable post-earnings drift following its August 2026 report. Heading into the third-quarter release, sentiment is largely tied to trial timelines and cash-burn trends rather than earnings surprises in the traditional sense. Key risk factors include the potential for higher-than-expected R&D spending, updated commentary on capital-raising constraints, and any shifts in the timing of clinical data readouts.

Forward Outlook and Key Factors to Monitor

The most important catalyst on LeonaBio's horizon is lasofoxifene, a selective estrogen receptor modulator (a type of hormone-based therapy) being studied in the Phase 3 (late-stage) ELAINE-3 trial for ESR1-mutated metastatic breast cancer. This ESR1 mutation is associated with resistance to standard endocrine therapy, and the company has said the trial is more than 50% enrolled with topline data expected in mid-2027.

Investors should also watch for progress on ATH-1105, LeonaBio's oral drug candidate for ALS, as the company prepares to advance it into Phase 2 testing. On the financial side, commentary on the cash runway — which management has said should reach into 2028 — and on research and development expense will be closely monitored.

One additional factor worth noting is the company's temporary ineligibility to use Form S-3 for registered offerings through December 2026, which limits certain expedited capital-raising options. How management addresses future financing needs, alongside clinical execution, will be central to the outlook following this report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations